Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Igor I. Rybkin, Ebenezer A. Kio, Ashiq Masood, Merrill Kingman Shum, Balazs Halmos, Collin M. Blakely, Keith D. Eaton, Neelesh Sharma, John J. Nemunaitis, Steven J. Saccaro, Yanis Boumber, Raul R. Mena, Hamid R. Mirshahidi, Pasi A. Janne, James Christensen, Richard C. Chao, Vanessa Roberts Tassell, Demiana Faltaos, Marshall T. Schreeder
Institutions: Henry Ford Health, Henry Ford Hospital, Goshen Health, Washington University in St. Louis, Oncology Institute of Hope and Innovation, Albert Einstein College of Medicine, Montefiore Medical Center, University of California, San Francisco, University of Washington, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Mary Crowley Cancer Research Center, CHRISTUS St. Frances Cabrini Hospital, Fox Chase Cancer Center, Loma Linda University Medical Center, Loma Linda University, Dana-Farber Cancer Institute, Mirati Therapeutics (United States), Clearview Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890565931